Affimed to Present at the 2022 Jefferies London Healthcare Conference

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced its CEO, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on November 16, 2022, at 12:55 p.m. GMT. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. Affimed is a clinical-stage immuno-oncology firm focused on enhancing patients' immune responses against cancer through its innovative ROCK® platform. The company aims to utilize the innate immune system to combat various tumors, showcasing a strong commitment to cancer research.

HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your Jefferies representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Affimed Investor Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Dr. Adi Hoess present at the Jefferies London Healthcare Conference?

Dr. Adi Hoess will present on November 16, 2022, at 12:55 p.m. GMT.

How can I access the live webcast of Affimed's presentation?

The live webcast can be accessed on Affimed’s website.

What is Affimed's focus in the healthcare industry?

Affimed focuses on clinical-stage immuno-oncology, aiming to empower patients' immune systems to fight cancer.

What is the ROCK® platform used by Affimed?

The ROCK® platform is designed to enhance the innate immune system's ability to target and kill tumors.

Where is Affimed headquartered?

Affimed is headquartered in Heidelberg, Germany.